Participant flow

Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma · Source last updated 2020-04-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   MAGE-A3, GM-CSF, Hiltonol® (Poly-ICLC), PCV vaccine prior to apheresis. Stem cell mobilization. High-dose melphalan, then hematopoietic stem cells on Day 0. Day 2 Activated/costimulated autologous T cells. Days 14, 42 and 90 MAGE-A3, Hiltonol® and PVC. Day 100 start Lenalidomide. Day 120 and 150 MAGE-A3 and PVC.

   id

   FG000

   title

   MAGE A-3, GM-CSF, Hiltonol®, T Cells, Lenalidomide,

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         28

      type

      STARTED

   2. achievements

      1. comment

         One subject failed to meet screening criteria for the trial.

         group Id

         FG000

         num Subjects

         27

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         1

      type

      NOT COMPLETED

   title

   Enrollment

2. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         27

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         27

      comment

      MAGE-A3, GM-CSF, Hiltonol®, PCV vaccine \~10 days before apheresis.

      type

      Pre Transplant Vaccinations 1-3

   3. achievements

      1. group Id

         FG000

         num Subjects

         27

      type

      COMPLETED

   4. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Pre Transplant Vaccinations

3. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         27

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         27

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Activated/Costimulated Autologous T Cell

4. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Off Study due to Disease Progression

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         27

      comment

      On study Days 14, 42 and 90 study participants will receive MAGE-A3, Hiltonol® and PVC vaccine.

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         26

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         1

      type

      NOT COMPLETED

   title

   MAGE-A3, Hiltonol®, PVC After T Cells

5. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         26

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         26

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Start Lenalidomide

6. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         26

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         26

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Maintenance: MAGE-A3, PVC After T Cells

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice